Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

Vaniprevir

HY-10243

(MK-7009; MK7009; MK 7009)

Vaniprevir

Vaniprevir Chemical Structure

Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease.

Size Price Stock Quantity
10 mM * 1 mL in DMSO $417 In-stock
5 mg $350 In-stock
10 mg $500 In-stock
50 mg Get quote
100 mg Get quote
Size Price Stock Quantity
10 mM * 1 mL in DMSO €409 In-stock
5 mg €343 In-stock
10 mg €490 In-stock
50 mg Get quote
100 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: Vaniprevir
Cat. No.: HY-10243

Vaniprevir Data Sheet

  • Network Version

    DataSheet

Related Compound Libraries

Biological Activity of Vaniprevir

Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease.
IC50 Value:
Target: HCV NS3/4A Protease; HCV
Vaniprevir (MK-7009) is a macrocyclic hepatitis C virus NS3/4a protease inhibitor, is active against both the genotype 1 and genotype 2 NS3/4a protease enzymes.  Vaniprevir (MK-7009)  has good plasma exposure and excellent liver exposure in multiple species.

Protocol (Extracted from published papers and Only for reference)

More

Chemical Information

M.Wt 757.94 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C38H55N5O9S
CAS No 923590-37-8
Solvent & Solubility

10 mM in DMSO

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 1.3194 mL 6.5968 mL 13.1937 mL
5 mM 0.2639 mL 1.3194 mL 2.6387 mL
10 mM 0.1319 mL 0.6597 mL 1.3194 mL

Clinical Information of Vaniprevir

Product Name Sponsor Only Condition Start Date End Date Phase Last Change Date
Vaniprevir Merck & Co Inc Hepatitis C virus infection 30-JUN-11 01-JUL-13 Phase 3 14-SEP-13
Merck & Co Inc Hepatitis C virus infection 30-JUN-10 31-MAY-13 Phase 2 04-JUL-13
Merck & Co Inc Hepatitis C virus infection 30-SEP-11 31-MAR-13 Phase 3 12-APR-13
Merck & Co Inc Hepatitis C virus infection 31-AUG-11 28-FEB-13 Phase 3 20-MAR-13
Merck & Co Inc Hepatitis C virus infection 31-MAR-09 30-SEP-12 Phase 2 20-NOV-13

References on Vaniprevir

[1]. Liverton, Nigel J.; Carroll, Steven S.; Di Muzio, Jillian;.MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrobial Agents and Chemotherapy (2009), Volume Date 2010, 54(1), 305-311.

[2]. Kong J, Chen CY, Balsells-Padros J, Cao Y, Dunn RF, Dolman SJ, Janey J, Li H, Zacuto MJ.Synthesis of the HCV protease inhibitor Vaniprevir (MK-7009) using ring-closing metathesis strategy.J Org Chem. 2012 Apr 20;77(8):3820-8. Epub 2012 Apr 10.

[3]. Manns MP, Gane E, Rodriguez-Torres M, Stoehr A, Yeh CT, Marcellin P, Wiedmann RT, Hwang PM, Caro L, Barnard RJ, Lee AW; for the MK-7009 Protocol 007 Study Group.Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-na?ve patients with chronic hepatitis C: A randomized phase II study.Hepatology. 2012 Sep;56(3):884-893.

[4]. Song ZJ, Tellers DM, Journet M, Kuethe JT, Lieberman D, Humphrey G, Zhang F, Peng Z, Waters MS, Zewge D, Nolting A, Zhao D, Reamer RA, Dormer PG, Belyk KM, Davies IW, Devine PN, Tschaen DM.Synthesis of vaniprevir (MK-7009): lactamization to prepare a 20-membered [corrected] macrocycle.J Org Chem. 2011 Oct 7;76(19):7804-15. Epub 2011 Aug 31.

[5]. McCauley JA, McIntyre CJ, Rudd MT, Nguyen KT, Romano JJ, Butcher JW, Gilbert KF, Bush KJ, Holloway MK, Swestock J, Wan BL, Carroll SS, DiMuzio JM, Graham DJ, Ludmerer SW, Mao SS, Stahlhut MW, Fandozzi CM, Trainor N, Olsen DB, Vacca JP, Liverton NJ.Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor.J Med Chem. 2010 Mar 25;53(6):2443-63.

Inhibitor Kit

Related HCV , HCV Protease Products

  • ABT-333

    ABT-333 is an NS5B non-nucleoside polymerase inhibitor.

  • Anguizole

    Anguizole is a small molecule inhibitor of HCV replication and alters NS4B(acute)s subcellular distribution.

  • Artemisinin

    Artemisinin (NSC 369397), a widely used anti-malarial drug, is an inhibitor of HCV subgenomic replicon replication.

  • Asunaprevir

    Asunaprevir (BMS-650032) is a potent hepatitis C virus (HCV) NS3 protease inhibitor.

  • Balapiravir

    Balapiravir (R1626, Ro 4588161) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479).

  • Boceprevir

    Boceprevir(EBP-520, SCH503034) is an HCV protease inhibitor (Ki=14 nM) for the treatment of hepatitis C virus infection.

  • Ciluprevir

    Ciluprevir(BILN 2061) is a specific and potent peptidomimetic inhibitor of the HCV NS3 protease with IC50 of 3.0 nM.

  • Danoprevir

    Danoprevir(ITMN-191;R7227; RO5190591;RG7227) is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A.

  • Elbasvir

    Elbasvir (MK-8742) is a small-molecule inhibitor of nonstructural protein 5A (NS5A) of hepatitis C virus (HCV) being developed as a component of treatment regimens for chronic HCV infection.

  • Helioxanthin

    Helioxanthin(ACH126447) and its analogues exhibit significant in vitro antiviral activity against hepatitis B virus (HBV, EC50=1 uM) and flavivirus.

MORE